These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 9801989

  • 1. Hexarelin, a synthetic GH-releasing peptide, is a powerful stimulus of GH secretion in pubertal children and in adults but not in prepubertal children and in elderly subjects.
    Bellone J, Bartolotta E, Sgattoni C, Aimaretti G, Arvat E, Bellone S, Deghenghi R, Ghigo E.
    J Endocrinol Invest; 1998 Sep; 21(8):494-500. PubMed ID: 9801989
    [Abstract] [Full Text] [Related]

  • 2. Age-related variations in the neuroendocrine control, more than impaired receptor sensitivity, cause the reduction in the GH-releasing activity of GHRPs in human aging.
    Arvat E, Ceda GP, Di Vito L, Ramunni J, Gianotti L, Broglio F, Deghenghi R, Ghigo E.
    Pituitary; 1998 Apr; 1(1):51-8. PubMed ID: 11081183
    [Abstract] [Full Text] [Related]

  • 3. Growth hormone response to hexarelin, growth hormone-releasing hormone plus pyridostigmine and arginine plus estrogen in prepubertal and early pubertal short children.
    Guzzaloni G, Grugni G, Morabito F.
    Minerva Endocrinol; 1998 Dec; 23(4):99-104. PubMed ID: 10361807
    [Abstract] [Full Text] [Related]

  • 4. The GH, prolactin, ACTH and cortisol responses to Hexarelin, a synthetic hexapeptide, undergo different age-related variations.
    Arvat E, Ramunni J, Bellone J, Di Vito L, Baffoni C, Broglio F, Deghenghi R, Bartolotta E, Ghigo E.
    Eur J Endocrinol; 1997 Dec; 137(6):635-42. PubMed ID: 9437229
    [Abstract] [Full Text] [Related]

  • 5. Reduction of the somatotrope responsiveness to GHRH and Hexarelin but not to arginine plus GHRH in hyperprolactinemic patients.
    Grottoli S, Razzore P, Arvat E, Oleandri SE, Rossetto R, Ciccarelli E, Camanni F, Ghigo E.
    J Endocrinol Invest; 1997 Nov; 20(10):597-602. PubMed ID: 9438917
    [Abstract] [Full Text] [Related]

  • 6. Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man.
    Arvat E, Di Vito L, Ramunni J, Gianotti L, Giordano R, Deghenghi R, Camanni F, Ghigo E.
    Clin Endocrinol (Oxf); 1997 Oct; 47(4):495-500. PubMed ID: 9404449
    [Abstract] [Full Text] [Related]

  • 7. The growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, in short normal and obese children and in hypopituitary subjects.
    Loche S, Cambiaso P, Carta D, Setzu S, Imbimbo BP, Borrelli P, Pintor C, Cappa M.
    J Clin Endocrinol Metab; 1995 Feb; 80(2):674-8. PubMed ID: 7852535
    [Abstract] [Full Text] [Related]

  • 8. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH.
    Arvat E, di Vito L, Maccagno B, Broglio F, Boghen MF, Deghenghi R, Camanni F, Ghigo E.
    Peptides; 1997 Feb; 18(6):885-91. PubMed ID: 9285939
    [Abstract] [Full Text] [Related]

  • 9. Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects.
    Arvat E, Gianotti L, Grottoli S, Imbimbo BP, Lenaerts V, Deghenghi R, Camanni F, Ghigo E.
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1440-3. PubMed ID: 7962341
    [Abstract] [Full Text] [Related]

  • 10. The GH-releasing effect of Hexarelin, a synthetic hexapeptide, in newborns is lower than in young adults.
    Bartolotta E, Bellone J, Aimaretti G, Arvat E, Benso L, Deghenghi R, Camanni F, Ghigo E.
    J Pediatr Endocrinol Metab; 1997 Nov; 10(5):491-7. PubMed ID: 9401905
    [Abstract] [Full Text] [Related]

  • 11. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, before and during puberty.
    Bellone J, Aimaretti G, Bartolotta E, Benso L, Imbimbo BP, Lenhaerts V, Deghenghi R, Camanni F, Ghigo E.
    J Clin Endocrinol Metab; 1995 Apr; 80(4):1090-4. PubMed ID: 7714074
    [Abstract] [Full Text] [Related]

  • 12. The growth hormone response to hexarelin in patients with Prader-Willi syndrome.
    Cappa M, Raguso G, Palmiotto T, Faedda A, Gurreri F, Neri G, Deghenghi R, Loche S.
    J Endocrinol Invest; 1998 Sep; 21(8):501-5. PubMed ID: 9801990
    [Abstract] [Full Text] [Related]

  • 13. Arginine enhances the growth hormone-releasing activity of a synthetic hexapeptide (GHRP-6) in elderly but not in young subjects after oral administration.
    Ghigo E, Arvat E, Rizzi G, Bellone J, Nicolosi M, Boffano GM, Mucci M, Boghen MF, Camanni F.
    J Endocrinol Invest; 1994 Mar; 17(3):157-62. PubMed ID: 8051337
    [Abstract] [Full Text] [Related]

  • 14. Diagnostic studies with intravenous and intranasal growth hormone-releasing peptide-2 in children of short stature.
    Pihoker C, Middleton R, Reynolds GA, Bowers CY, Badger TM.
    J Clin Endocrinol Metab; 1995 Oct; 80(10):2987-92. PubMed ID: 7559885
    [Abstract] [Full Text] [Related]

  • 15. Effects of histaminergic antagonists on the GH-releasing activity of GHRH or hexarelin, a synthetic hexapeptide, in man.
    Arvat E, Maccagno B, Ramunni J, Gianotti L, Di Vito L, Deghenghi R, Camanni F, Ghigo E.
    J Endocrinol Invest; 1997 Mar; 20(3):122-7. PubMed ID: 9186817
    [Abstract] [Full Text] [Related]

  • 16. Low dose hexarelin and growth hormone (GH)-releasing hormone as a diagnostic tool for the diagnosis of GH deficiency in adults: comparison with insulin-induced hypoglycemia test.
    Gasperi M, Aimaretti G, Scarcello G, Corneli G, Cosci C, Arvat E, Martino E, Ghigo E.
    J Clin Endocrinol Metab; 1999 Aug; 84(8):2633-7. PubMed ID: 10443652
    [Abstract] [Full Text] [Related]

  • 17. Reduction of the pituitary GH releasable pool in short children with GH neurosecretory dysfunction.
    Aimaretti G, Bellone S, Bellone J, Chiabotto P, Baffoni C, Corneli G, Origlia C, de Sanctis C, Camanni F, Ghigo E.
    Clin Endocrinol (Oxf); 2000 Mar; 52(3):287-93. PubMed ID: 10718826
    [Abstract] [Full Text] [Related]

  • 18. Further evidence of cholinergic impairment of the neuroendocrine control of the GH secretion in Down's syndrome.
    Beccaria L, Marziani E, Manzoni P, Arvat E, Valetto MR, Gianotti L, Ghigo E, Chiumello G.
    Dement Geriatr Cogn Disord; 1998 Mar; 9(2):78-81. PubMed ID: 9524798
    [Abstract] [Full Text] [Related]

  • 19. Low dose orally administered arginine is able to enhance both basal and growth hormone-releasing hormone-induced growth hormone secretion in normal short children.
    Bellone J, Bartolotta E, Cardinale G, Arvat E, Cherubini V, Aimaretti G, Maccario M, Mucci M, Camanni F, Ghigo E.
    J Endocrinol Invest; 1993 Mar; 16(7):521-5. PubMed ID: 8227981
    [Abstract] [Full Text] [Related]

  • 20. Growth hormone (GH) responsiveness to combined administration of arginine and GH-releasing hormone does not vary with age in man.
    Ghigo E, Goffi S, Nicolosi M, Arvat E, Valente F, Mazza E, Ghigo MC, Camanni F.
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1481-5. PubMed ID: 2229304
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.